Maintenance therapy with peginterferon Alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C

Jordi Bruix, Thierry Poynard, Massimo Colombo, Eugene Schiff, Kelly Burak, Elizabeth J.L. Heathcote, Thomas Berg, Jorgeluis Poo, Carlos Brandao Mello, Rainer Guenther, Claus Niederau, Ruben Terg, Pierre Bedossa, Navdeep Boparai, Louis H. Griffel, Margaret Burroughs, Clifford A. Brass, Janice K. Albrecht

Research output: Contribution to journalArticle

87 Scopus citations

Abstract

Background & Aims: Several studies have reported that low doses of interferon can delay the development of hepatocellular carcinoma (HCC) and progression of chronic hepatitis C. We investigated the incidence of clinical events among participants of the Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC)3 program. Methods: Data were analyzed from an open-label randomized study of patients with chronic hepatitis C who had failed to respond to interferon alfa plus ribavirin. All patients had compensated cirrhosis with no evidence of HCC. Patients received peginterferon alfa-2b (0.5 μg/kg/week; n = 311) or no treatment (controls, n = 315) for a maximum period of 5 years or until 98 patients had a clinical event (hepatic decompensation, HCC, death, or liver transplantation). The primary measure of efficacy was time until the first clinical event. Results: There was no significant difference in time to first clinical event among patients who received peginterferon alfa-2b compared with controls (hazard ratio [HR], 1.452; 95% confidence interval [CI]: 0.8802.396). There was no decrease in the development of HCC with therapy. The time to disease progression (clinical events or new or enlarged varices) was significantly longer for patients who received peginterferon alfa-2b compared with controls (HR, 1.564; 95% CI: 1.1302.166). In a prospectively defined subanalysis of patients with baseline portal hypertension, peginterferon alfa-2b significantly increased the time to first clinical event compared with controls (P = .016). There were no new safety observations. Conclusions: Maintenance therapy with peginterferon alfa-2b is not warranted in all patients and does not prevent HCC. However, there is a potential clinical benefit of long-term suppressive therapy in patients with preexisting portal hypertension.

Original languageEnglish (US)
Pages (from-to)1990-1999
Number of pages10
JournalGastroenterology
Volume140
Issue number7
DOIs
StatePublished - Jun 2011

Keywords

  • Clinical Trial
  • EPIC Program
  • Evaluation of PegIntron in Control of Hepatitis C Cirrhosis Program
  • Liver Cancer

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Maintenance therapy with peginterferon Alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C'. Together they form a unique fingerprint.

  • Cite this

    Bruix, J., Poynard, T., Colombo, M., Schiff, E., Burak, K., Heathcote, E. J. L., Berg, T., Poo, J., Mello, C. B., Guenther, R., Niederau, C., Terg, R., Bedossa, P., Boparai, N., Griffel, L. H., Burroughs, M., Brass, C. A., & Albrecht, J. K. (2011). Maintenance therapy with peginterferon Alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology, 140(7), 1990-1999. https://doi.org/10.1053/j.gastro.2011.03.010